DRUG PRIOR AUTHORIZATION COMMITTEE
September 17, 2015

TENTATIVE AGENDA

Department of Natural Resources
1101 Riverside Dr.
Lacharette/Nightengale Rooms
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Steve Calloway/Andrew Haslag
10:25 - 10:35	DUR Update	Steve Calloway

Old Business

10:35 – 10:45	**A.** Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Steve Calloway

New Business

10:45 – 11:30 **B. Proposed** Actions **- New Drug/Product Review** Steve Calloway
(See website and Attached Summary)

- **i. Open Access**
- **ii. Clinical Edit/Step Therapy**
- **iii. PDL Products**
- **iv. Prior Authorization**
  - Discussion
  - Public Hearing
  - Decision

11:30 – 11:45 **C. Clinical Edits**

11:45 – 1:00 **D. Preferred Drug List (PDL)**

- **I. ACE Inhibitor Agents**
  - Discussion
  - Public Hearing
  - Decision
- **II. ACE Inhibitors/Calcium Channel Blocker Combination Agents**
  - Discussion
  - Public Hearing
  - Decision

III. ACE Inhibitors/Diuretic Combination Agents

- Discussion
- Public Hearing
- Decision

IV. Angiotensin Receptor Blocker Agents (ARB's)

- Discussion
- Public Hearing
- Decision

V. Angiotensin Receptor Blocker/Diuretic Combination Agents

- Discussion
- Public Hearing
- Decision

VI. Angiotensin Receptor/Calcium Channel Blocker Combination Agents

- Discussion
- Public Hearing
- Decision

VII. Anticoagulant Agents: Oral and Subcutaneous

- Discussion
- Public Hearing
- Decision

VIII. Beta Adrenergic Blockers and Diuretic Combination Agents

- Discussion
- Public Hearing
- Decision

IX. Calcium Channel Blocker Agents (Dihydropyridines)

- Discussion
- Public Hearing
- Decision

X. Calcium Channel Blocker Agents (Non-Dihydropyridines)

- Discussion
- Public Hearing
- Decision

XI. Direct Renin Inhibitors and Combination Agents

- Discussion
- Public Hearing
- Decision

XII. Homozygous Familial Hypercholesterolemia Products

- Discussion
- Public Hearing
- Decision

XIII. Lipotropic Agents: Niacin and Combination Preparations

- Discussion
- Public Hearing
- Decision

XIV. Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products

- Discussion
- Public Hearing
- Decision

XV. Proton Pump Inhibitor Agents

- Discussion
- Public Hearing
- Decision

XVI. Pulmonary Hypertension Agents: Inhaled/Injectable

- Discussion
- Public Hearing
- Decision

XVII. Pulmonary Hypertension Agents: Oral

- Discussion
- Public Hearing
- Decision

XVIII. Triglyceride Lowering Agents

- Discussion
- Public Hearing
- Decision

E. <u>Preferred Drug List Classes for Dec/Jan</u>

i. Process Discussion
ii. Therapeutic classes/to be announced at meeting

1:00	**LUNCH**	
1:15-1:30	**Program Utilization Information-Xerox Update**	Steve Calloway/ Josh Moore
1:30-1:50	**Other Business**	

- *"Top 25" Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: December 17, 2015

Department of Natural Resources - 1101 Riverside Dr.

Lacharrette/Nightengale Rooms